209 results about "Bifidobacterium breve" patented technology

The invention relates to a weight-losing enzyme and a preparation method thereof, and belongs to the technical field of biology, and the weight-losing enzyme comprises a fruit enzyme, a vegetable enzyme, a seed enzyme and a lotus leaf extract; the fruit enzyme is obtained by performing enzymolysis on mixed fruit pulp of apples, lemons, grapefruits and haws through pectinase, performing enzymolysis through pepsase and performing co-fermentation through bifidobacterium longum and lactobacillus acidophilus; the vegetable enzyme is obtained by performing enzymolysis on mixed vegetable pulp of wax gourd pulp, celery and spinach through pectinase, performing enzymolysis through pepsin and performing fermentation through lactobacillus plantarum and bifidobacterium adolescentis; the seed enzyme is obtained by carrying out trypsin enzymolysis on mixed powder of semen raphani and phaseolus calcaratus, then carrying out nattokinase enzymolysis and then fermenting with bifidobacterium breve; the lotus leaf extract is obtained by sequentially carrying out enzymolysis on lotus leaves through hemicellulase, snail protease and nattokinase. All the components are matched for use, so that the weight-losing food has the effects of promoting digestion, inhibiting fat absorption, regulating intestinal flora, promoting metabolism and the like, and has a good weight-losing effect.

The invention discloses bifidobacterium breve BBr69 with an immunoregulation function as well as application, a product and a method thereof, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium breve BBr69 with the immunoregulation function is CGMCC (China General Microbiological Culture Collection Center) NO. 32425. Based on the strain, the invention also provides application and related products of the strain. The BBr69 strain has broad-spectrum antibacterial performance, has the function of regulating intestinal flora and also has the function of enhancing immunity, and immunity is enhanced by proliferating RAW264.7 cells, increasing the content of cell factors, inhibiting weight loss, increasing the index of immune organs and reducing ileum tissue damage.

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.

The invention discloses bifidobacterium breve and application thereof in relieving Alzheimer's disease, and belongs to the technical field of probiotics. The preparation method comprises the following steps: separating 18 bifidobacterium strains from feces of children aged 0-3 years old, analyzing and identifying the 18 bifidobacterium strains including bifidobacterium longum, bifidobacterium breve and bifidobacterium animalis, and screening out the bifidobacterium breve LE4 with potential Alzheimer's disease relieving capacity through in-vitro oxidation resistance and LPS (Lipopolysaccharide) removal capacity. The method comprises the steps of behavioral experiments (nesting experiments, open field experiments and water maze experiments), histopathologic analysis, molecular biological detection and the like. The multi-target AD intervention effects of improving the cognitive function, reducing A beta deposition and tau protein phosphorylation, relieving neuroinflammation, enhancing synaptic plasticity, repairing intestinal barriers, adjusting intestinal flora and metabolites and the like of the LE4 strain are comprehensively evaluated, and a new strategy is provided for promoting AD micro-ecological treatment.

The invention provides bifidobacterium breve BX-18 and application thereof, and belongs to the technical field of biology. The preservation number of the Bifidobacterium breve BX-18 provided by the invention is CGMCC (China General Microbiological Culture Collection Center) No.28446. The Bifidobacterium breve BX-18 provided by the invention has the advantages that the preservation number is CGMCC No.28446; the bifidobacterium breve BX-18 can be used for synthesizing amino acids and metabolites thereof, benzene derivatives, flavonoids and other active substances, and the metabolites of the bifidobacterium breve BX-18 have broad-spectrum antibacterial activity and have a good antibacterial effect on food-borne pathogenic bacteria or putrefying bacteria. The invention provides a brand new thought for deep research and utilization of probiotics with functional active substances, and has huge research and application values.

The invention relates to a preparation method of a rice leavening with a scalp care effect and a product and application thereof, the preparation method comprises the following steps: mixing a rice raw material, a plant raw material, water, a magnesium salt, a sodium salt and Tween, sterilizing to obtain a fermentation medium, inoculating a compound microbial agent into the fermentation medium, and fermenting to obtain the rice leavening with the scalp care effect. After the fermentation liquid is finished, sterilizing and filtering to obtain a rice leavening; wherein the compound microbial agent comprises a first microbial strain and a second microbial strain; the strains in the first microbial strain comprise a combination of streptococcus thermophilus, bifidobacterium breve and a plant lactobacillus YK-L002 strain; and the second microbial strain comprises a trichosporon YK-S004 strain. According to the invention, specific strains are subjected to compounding and combined fermentation, and the fermentation product filtrate obtained after fermentation treatment of four bacteria has excellent hair care and nourishing effects, and can effectively condition the scalp micro-ecological environment and nourish the hair quality.

The invention belongs to the technical field of traditional Chinese medicine patches, mainly relates to a traditional Chinese medicine patch and a preparation method thereof, and in particular relates to a patch for treating cough and asthma and a preparation process thereof. Natural plants including the semen brassicae, the pink reineckea herb and the modified herba ephedrae are selected, the performance is improved through synergistic fermentation of the lactobacillus acidophilus CICC-22162 and the bifidobacterium breve CICC-6184, the effect of treating cough and asthma of the traditional Chinese medicine is improved, meanwhile, under the fermentation condition, the effect of treating diarrhea is achieved under the synergistic effect of leavening of the semen brassicae and the pink reineckea herb, and the traditional Chinese medicine composition has a good application prospect. In addition, the perillaseed extracting solution and the asarum extracting solution which are used in the patch have extremely high oxidation resistance under the synergistic effect, so that the stability of the patch is effectively improved, and the shelf life of the patch is prolonged.

The invention relates to an application of bifidobacterium breve i1088 or a postbiotic thereof in improvement of cognition. The bifidobacterium breve i1088 or the afterbiogen of the bifidobacterium breve i1088 is used for preparing a product for enhancing the oxidative stress capacity of mammalian cells, improving the in-vitro free radical scavenging level of mammals and changing at least one of the expression levels of mammalian cells Nrf2 and anti-oxidation related genes. The invention aims to explore the potential of the bifidobacterium breve in the aspect of improving the Alzheimer's disease and provide a safer and more effective nutritional supplement scheme for middle-aged and elderly people.

The invention discloses a preparation method of high-stability beta-glucan yoghourt. Mixing the sterilized fresh milk with a composite strain consisting of lactobacillus delbrueckii subsp. Bulgaricus, streptococcus salivarius subsp. Thermophilus, bifidobacterium animalis subsp. Lactis, plant lactobacillus, bifidobacterium breve, lactobacillus paracasei, lactobacillus helveticus, lactobacillus rhamnosus and bifidobacterium longum subsp. Longum, and fermenting; and adding beta-glucan into the fermented yoghourt to obtain the high-stability beta-glucan yoghourt. Before beta-glucan is added, the compound bacterial strain is added into the milk, protein in the milk can be gathered under the action of the compound bacterial strain to form a three-dimensional curd network, so that the flowability of a system is reduced, then glucan is added, and the glucan can be uniformly dispersed in curd gaps, so that the glucan is prevented from being excessively combined with the protein in the milk; the stability of a yoghourt system is improved.

The present invention discloses a Bifidobacterium breve strain capable of clearing toxins in the body and its postbiotics, belonging to the technical field of microbial applications. The present invention isolates a Bifidobacterium breve strain ( Bifidobacterium breve ) WZA-BB07 from human feces, and its biological deposit number is: CCTCC NO: M20241530. The strain WZA-BB07 has good effects in degrading endotoxin and enterotoxin. The strain and Lactobacillus mucosae are mixed and fermented to prepare postbiotics. Bifidobacterium breve mainly improves the balance of intestinal flora and inhibits the growth of harmful bacteria. Lactobacillus mucosae helps repair the intestinal barrier through its metabolites during fermentation, enhancing the metabolism and clearance of toxins; extracts of Dendrobium officinale, Lonicera japonica, and Pueraria lobata are added to the fermentation medium, which not only provides rich nutrition for fermentation but also exerts the antioxidant, anti-inflammatory, and intestinal repair-promoting effects of ingredients with both medicinal and edible properties, further enhancing the detoxification ability and overall health effects of the postbiotic product.

The invention belongs to the technical field of biological medicines, discloses application of bifidobacterium breve BB990 in the field of metabolism, and particularly discloses bifidobacterium breve BB990 which is preserved in Guangdong Microorganism Culture Collection Center, the preservation number is GDMCC No.63259, and the preservation date is March 10, 2023. The invention further discloses a preparation method of the bifidobacterium breve BB990. The bifidobacterium breve BB990 provided by the invention has the effects of regulating gastrointestinal disorder, enhancing intestinal immune function, inhibiting harmful bacteria, improving intestinal flora structure, maintaining intestinal steady state, regulating immunity, improving immune curative effect, regulating body glycometabolism and liver metabolism and the like. Experiments prove that the bifidobacterium breve BB990 can effectively prevent and treat metabolic diseases, such as non-alcoholic fatty liver, type II diabetes and the like, the treatment effect of the bifidobacterium breve BB990 is remarkably superior to that of other bifidobacterium breve (such as bifidobacterium breve 206), and the bifidobacterium breve BB990 has a good prospect.

The invention relates to application of bifidobacterium breve BBr60 in preparation of a probiotic preparation for improving atopic dermatitis. The bifidobacterium breve BBr60 is a bifidobacterium breve BBr60 strain of which the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.12915, and the bifidobacterium breve BBr60 strain of which the preservation number is CGMCC No.12915. The invention develops a new application of the bifidobacterium breve BBr60, provides a research basis for wide application of the bifidobacterium breve BBr60, also develops a brand new strategy for improving atopic dermatitis, discovers that the bifidobacterium breve BBr60 has a very remarkable effect on improving atopic dermatitis, and has a very good application prospect. Specifically, the skin lesion phenomenon and the mast cell inflammation infiltration phenomenon in the skin of an atopic dermatitis model mouse are remarkably improved; the IgE level in serum of an atopic dermatitis model mouse is remarkably reduced and improved, the levels of IFN-gamma and IL-10 are improved, and Th1 / Th2 immune balance is recovered; the intestinal flora uniformity of atopic dermatitis model mice is recovered, and the relative abundance and F / B ratio of bifidobacterium and lactobacillus in the intestinal flora of the mice are remarkably improved.

The invention discloses a prebiotic composition capable of proliferating bifidobacterium and application of the prebiotic composition. The prebiotic composition comprises polydextrose, isomaltooligosacharide and galactooligosaccharide. Wherein the mass ratio of the polydextrose to the isomaltooligosacharide to the galactooligosaccharide is (0-2): (3-5): (4-5). The prebiotic composition provided by the invention can increase the content of total bifidobacteria in intestinal tracts, especially can specifically proliferate bifidobacteria longum and bifidobacteria breve, and can accurately regulate and control intestinal flora, thereby accurately intervening in host health.

The invention discloses bifidobacterium breve BBr26 capable of inhibiting hyaluronidase activity and relieving allergy as well as an application, a product and a method of the bifidobacterium breve BBr26, and belongs to the technical field of microorganisms. The invention provides a Bifidobacterium breve (Bifidobacterium breve) strain BBr26 with anti-allergy and / or immunoregulation capability, and the preservation number of the Bifidobacterium breve strain BBr26 is CGMCC (China General Microbiological Culture Collection Center) NO.32424. The invention also provides a preparation method of the Bifidobacterium breve strain The invention also provides an application of the strain bifidobacterium breve BBr26 in preparation of products for relieving atopic dermatitis, and / or food for enhancing immune function, and / or bacteriostatic agents, and a product and a method based on the strain BBr26. The strain disclosed by the invention has broad-spectrum bacteriostasis, can relieve allergy and atopic dermatitis, and can effectively play a role in immunoregulation.

The invention relates to the technical field of probiotics, in particular to a lactic acid bacteria strain composition with an effect of improving sleep quality and application. The lactic acid bacteria strain composition comprises a bifidobacterium breve BBr-28 strain, a bifidobacterium animalis subsp. Lactis PS23 strain, a bifidobacterium longum subsp. Infantis BR631 strain, a bifidobacterium bifidum BD-188 strain and a plant lactobacillus PQQ-1 strain. The lactic acid bacteria strain composition has the physiological activity function of improving the sleep quality, so that the lactic acid bacteria strain composition can be used for preparing food or composition for improving the sleep quality, and the problem of poor sleep quality is solved.

Provided is a Bifidobacterium breve for improving an aging-related cognitive disorder and use thereof. The Bifidobacterium breve for improving the aging-related cognitive disorder is named Bifidobacterium breve BBr16 strain with a deposit number CGMCC No. 24471. The strain can significantly improve the aging-related cognitive disorder and can be used for preparing a product with an efficacy of preventing, improving or treating the aging-related cognitive disorder.

The invention relates to the technical field of probiotics, in particular to a lactic acid bacteria strain composition for improving sleep quality and application, and the lactic acid bacteria strain composition comprises a bifidobacterium breve BBr-28 strain, a bifidobacterium animalis subsp. Lactis PS23 strain, a bifidobacterium longum subsp. Infantis BR631 strain and a cheese paracasei BR176 strain. The lactic acid bacteria strain composition has the physiological activity function of improving the sleep quality, so that the lactic acid bacteria strain composition can be used for preparing the composition for improving the sleep quality so as to improve the sleep quality.

The present invention relates to a uric acid-lowering probiotic complex and its application. The probiotic complex comprises Lactobacillus reuteri FPH2951 and Bifidobacterium breve FPHC4024; wherein Lactobacillus reuteri FPH2951 is classified as Lactobacillus reuteri and has a deposit number of GDMCC No. 62946; and Bifidobacterium breve FPHC4024 is classified as Bifidobacterium breve and has a deposit number of GDMCC No. 62945. The probiotic complex of the present invention can significantly reduce serum uric acid (UA), creatinine (Cr), and blood urea nitrogen (BUN) levels and increase urine excretion of creatinine (Cr) and blood urea nitrogen (BUN) through the synergistic effect of Lactobacillus reuteri FPH2951 and Bifidobacterium breve FPHC4024, and has broad application prospects.

The invention relates to a probiotic preparation for improving Parkinson's disease and an application of the probiotic preparation. The bacterial strains in the probiotic preparation comprise an Ackermania muciniphila Akk11 bacterial strain and a Bifidobacterium breve BBr60 bacterial strain. The invention further relates to a preparation method of the probiotic preparation for improving the Parkinson's disease and an application of the probiotic preparation for improving the Parkinson's disease, wherein the bacterial strains in the probiotic preparation comprise the Ackermania muciniphila Akk11 bacterial strain and the Bifidobacterium breve BBr60 bacterial strain. The invention develops a brand-new probiotic compounding mode and a brand-new probiotic intervention strategy for improving the Parkinson's disease, that is, the Akk11 strain and the BBr60 strain are compounded, and the two strains are found to have potential interaction and can be matched with each other, so that a synergistic effect is achieved on the aspect of improving the Parkinson's disease, and the effect of improving the Parkinson's disease is achieved. Specifically, the traditional Chinese medicine composition synergistically improves dyskinesia caused by Parkinson's disease, reduces expression of related inflammatory factors in nigra, promotes generation of anti-inflammatory factors to relieve neurological inflammation, inhibits activation of inflammasome NLPR3 in nigra, and further inhibits brain inflammation.

The invention belongs to the technical field of biological medicines, and particularly relates to application of bifidobacterium breve and lactoferrin in preparation of products for regulating intestinal flora or resisting bacterial infection. The invention provides application of Bifidobacterium breve HH079 with the preservation number of GDMCC No: 64216 and lactoferrin in preparation of a product for regulating intestinal flora or a product for resisting bacterial infection, and the Bifidobacterium breve HH079 and the lactoferrin are combined and synergistically used for resisting the bacterial infection. The composition can reverse weight loss, colon shortening, bacterial load increase and colon epithelium injury caused by bacterial infection, can significantly inhibit the level of proinflammatory cytokines, promote the expression of anti-inflammatory cytokines, can significantly increase the concentration of acetic acid and propionic acid in excrement of infected mice, can generate positive regulation on intestinal flora, and can inhibit bacterial infection. Good application prospects are shown in regulation of intestinal flora and bacterial infection resistance.

The invention relates to a polygonatum sibiricum probiotic compound preparation with an aging delaying effect and application thereof. The compound preparation comprises a polygonatum sibiricum extract and a probiotic composition, the bacterial strains in the probiotic composition comprise a combination of a bifidobacterium animalis subsp. Lactis BLa36 bacterial strain, a bifidobacterium longum BL21 bacterial strain, a bifidobacterium adolescentis BAC30 bacterial strain, a lactobacillus plantarum Lp90 bacterial strain, a lactobacillus casei LC89 bacterial strain, a bifidobacterium breve BBr60 bacterial strain and a pediococcus acidilactici CCFM7902 bacterial strain. After the rhizoma polygonati component and the probiotic component are combined for use, the rhizoma polygonati component and the probiotic component have potential synergistic effects in the aspects of improving the intestinal flora structure, regulating the intestinal environment, delaying senescence, reducing inflammation-related symptoms and the like. Moreover, further, various probiotic strains are compounded and combined for use, so that the capability of a related compound preparation in the aspect of delaying various symptoms of senescence can also be improved in a combined manner.

The invention discloses bifidobacterium breve for relieving ulcerative colitis and improving constipation and application of the bifidobacterium breve, and belongs to the field of microorganisms. The bifidobacterium breve LIHUO 02 provided by the invention has the preservation number of GDMCC No: 65513, and is preserved in the Guangdong Microbial Culture Collection Center on November 20, 2024, and the preservation number of the bifidobacterium breve LIHUO 02 is CGMCC No: 65513. The probiotic performance of the bifidobacterium breve LIHUO 02 is verified through a plurality of experiments, and the strain has a good application prospect.

Provided are a probiotic formulation for preventing or treating Alzheimer's disease and use thereof. The microorganisms in the probiotic formulation consist of Akkermansia muciniphila and Bifidobacterium breve. Akkermansia muciniphila and Bifidobacterium breve can coordinate with each other after being compounded, so as to provide a synergistic effect on alleviating Alzheimer's disease and thereby a new strategy for preventing or treating Alzheimer's disease. Since Akkermania muciniphila and Bifidobacterium breve are both probiotics, a related functional product prepared from Akkermania muciniphila and Bifidobacterium breve may feature good safety and less likelihood of inducing resistance.

The invention discloses a novel application of bifidobacterium breve CCFM1078 in relieving atopic dermatitis, and belongs to the technical field of microorganisms. The bifidobacterium breve CCFM1078 provided by the invention can relieve atopic dermatitis, and is specifically reflected in that (1) ear swelling and back skin thickening of mice are relieved, dermatological symptoms are relieved, and mastocyte infiltration is reduced; (2) the relative expression quantity of mRNA (messenger Ribonucleic Acid) of mouse skin barrier function related genes is increased; (3) reducing the total IgE level of mouse serum; (4) reducing the levels of IL-4, IL-13 and TSLP in mouse skin tissues, improving the levels of IL-10 and IFN-gamma, recovering Th1 / Th2 immune balance, and maintaining immune homeostasis; (5) activating the expression of AHR and CYP1A1 in the skin tissue of the mouse; (6) improving IgA and sIgA secretion of mouse colon tissue; and (7) compared with a representative high-yield ILA strain, the ILA yield is higher.

The invention discloses bifidobacterium breve with hypoglycemic capacity and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides a bifidobacterium breve (Bifidobacterium breve) strain BBr37 with the blood sugar reducing capacity, and the preservation number of the bifidobacterium breve strain BBr37 is CGMCC (China General Microbiological Culture Collection Center) NO.32423. The invention also provides an application of the strain BBr37 in preparation of hypoglycemic drugs or health-care foods with an auxiliary hypoglycemic function or bacteriostatic agents or non-treatment-destination bacteriostasis, and a product and a method based on the strain BBr37. The strain BBr37 disclosed by the invention has a relatively strong inhibition effect on escherichia coli, staphylococcus aureus, salmonella, haemophilus parasuis, haemophilus parainfluenza, campylobacter jejuni and enterocolitis yarrowia, and can effectively achieve the effects of reducing blood sugar and regulating intestinal flora.

The invention provides application of bifidobacterium breve in preparation of a product for resisting gastric ulcer and gastric inflammation caused by helicobacter pylori, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium breve NKU BB1-2 is GDMCC NO: 65956, and the bifidobacterium breve NKU BB1-2 can antagonize helicobacter pylori colonization and relieve gastric ulcer aggravation caused by helicobacter pylori. The bifidobacterium breve NKU BB 1-2 has good helicobacter pylori antagonism ability in an in-vitro environment, and can significantly inhibit colonization growth of helicobacter pylori; animal experiments show that the bifidobacterium breve NKU BB 1-2 can relieve gastric ulcer aggravation caused by helicobacter pylori infection in vivo, and the gastric mucosa lesion is relieved, the stomach inflammation is relieved, and the stomach pH value is increased; in addition, the bifidobacterium breve NKU BB1-2 can also significantly improve the diversity of stomach microorganisms, regulate and improve the structure of the stomach microorganisms, and assist antagonism and removal of helicobacter pylori infection.

The invention relates to a compound probiotic formula, a preparation and application of the compound probiotic formula. The compound probiotic formula is prepared from bifidobacterium animalis HN019, bifidobacterium animalis Bb-12, bifidobacterium breve M-16V, lactobacillus rhamnosus HN001 and lactobacillus acidophilus NCFM. The ratio of the viable count of the bifidobacterium animalis HN019 to the viable count of the bifidobacterium animalis Bb-12 to the viable count of the bifidobacterium breve M-16V to the viable count of the lactobacillus rhamnosus HN001 to the viable count of the lactobacillus acidophilus NCFM is 2.5 to 1.2 to 1.3 to 2.5 to 2.5. The traditional Chinese medicine composition has the advantages of helping to establish intestinal flora balance, improving immunity, preventing infectious diseases, regulating immune balance, preventing and relieving eczema and allergy, bidirectionally regulating diarrhea and constipation, relieving gastrointestinal function discomfort symptoms, improving poor appetite, anorexia and dyspepsia, improving children crying and screaming at night and poor sleep, improving children growth and development retardation, and improving children immunity. Social emotion behaviors of children are improved, and attention deficits are improved; the probiotic composition can coexist and symbiotic, induces an organism to establish intestinal flora balance, relieves food allergy symptoms, and improves social emotion problems caused by food allergy.

The invention belongs to the technical field of fermentation and metagen preparations, and particularly relates to application of bifidobacterium breve metagen in the aspects of scavenging free radicals and relieving oxidative aging. According to the present invention, the oxidative free radical scavenging experiment results show that the bifidobacterium breve NKU BB 1-2 metagen has good oxidative free radical scavenging ability, and has good scavenging ability on hydroxyl free radicals, superoxide anions and DPPH free radicals; meanwhile, through component analysis, it is found that the bifidobacterium breve NKU BB 1-2 metagen contains various antioxidant and anti-aging bioactive substances such as flavonoids, indoles, amino acids, bile acids and ceramides; a cell model experiment verifies that the bifidobacterium breve NKU BB 1-2 metagen can obviously relieve oxidative damage to the cells and improve the oxidation resistance of the cells, so that oxidative aging is relieved.

The invention belongs to the technical field of microorganisms, and relates to a bifidobacterium breve strain capable of relieving constipation, the strain is bifidobacterium breve Bb-PG-14, the classification name of the strain is Bifidobacterium breve, the preservation number is CGMCC No.31861, the preservation time is September 4, 2024, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, the preservation number is CGMCC No.31861, and the preservation number is CGMCC No.31861. The address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain is separated and purified from excrement of healthy babies, has relatively strong acid resistance, alkali resistance, cholate resistance and artificial simulated gastrointestinal fluid tolerance, and has the characteristics of probiotics.

The present invention provides a nutritional composition comprising at least one lactose-N-fucose pentasaccharide, in particular lactose-N-fucose pentasaccharide-I (LNFP-I) or a combination of lactose-N-fucose pentasaccharide-I (LNFP-I), lactose-N-fucose pentasaccharide-II (LNFP-II) and lactose-N-fucose pentasaccharide-III (LNFP-III), for use in improving brain development and / or cognitive development in a subject. There is also provided a nutritional composition comprising at least one lactose-N-fucopentasaccharide, in particular lactose-N-fucopentasaccharide-I (LNFP-I) or a combination of lactose-N-fucopentasaccharide-I (LNFP-I), lactose-N-fucopentasaccharide-II (LNFP-II) and lactose-N-fucopentasaccharide-III (LNFP-III), and Bifidobacterium bifidobacterium.